Mankyu Park
Director/Board Member chez Coagulant Therapeutics, Inc.
Profil
Mankyu is a Principal at DTCP in the Growth Equity team and covers Korea-based investments.
Mankyu came to DTCP from L&S Venture Capital, a leading Korean VC specializing in IT, semiconductors, and display investments.
Prior to that he held positions in the investment banking division of KB Securities and at Partners Group.
Mankyu made investments in IT, AI, Bio/Life science, mobile platforms, and other tech sectors.
Mankyu also led a couple of mid-to-large size deals like Youngin Engineering and Coagulant Therapeutics where top-tier Korean local VCs participated.
Mankyu holds a bachelor’s degree in business administration with concentration on finance from Goizueta Business School, Emory University.
Postes actifs de Mankyu Park
| Sociétés | Poste | Début |
|---|---|---|
Coagulant Therapeutics, Inc.
 Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Director/Board Member | - |
Anciens postes connus de Mankyu Park
| Sociétés | Poste | Fin |
|---|---|---|
| DTCP Management GmbH | Corporate Officer/Principal | - |
Formation de Mankyu Park
| Goizueta Business School-Emory | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
| DTCP Management GmbH | Finance |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Health Technology |
